Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorArovella Therapeutics Ltd
About this trial
Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101
Eligibility criteria
Qualifiers
Over 18 years old
Confirmed Diagnoses of Confirmed diagnosis of CD19+ non-Hodgkins lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphatic Leukemia or Hairy Cell Leukemia
Life Expectancy greater than 3 months
Adequate Hepatic and Renal Function
Disqualifiers
Prior anti-CD1d monoclonal antibody treatment
Prior allogeneic stem cell transplant except where the participant is greater than 100 days and does not have Graft Versus Host Disease (uncontrolled)
Prior Organ Transplant
Previous Malignancy in last 3 years that's active or been treated.
Trial design
Treatments tested in this trial
- ALA-101
Treatment groups
46 Participants
are divided into 5 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov